Longevity Scientist David Sinclair to Test Whole-Body Rejuvenation Drugs in XPrize Competition

The outspoken longevity scientist David Sinclair has long envisioned a future where a simple prescription could make individuals a decade younger. Now, this ambitious prediction is moving closer to reality, as MIT Technology Review has revealed his plans to launch human trials for an oral "reprogramming" drug. This groundbreaking initiative is part of the $101 million XPrize competition, a global challenge designed to incentivize teams capable of "restoring" a person to an earlier apparent age by improving immune, cognitive, and muscle function. The XPrize Foundation offers substantial cash awards, with the grand prize reserved for any team demonstrating a 10-year or greater relative improvement in biological age after just one year of treatment. Sinclair, a distinguished biologist at Harvard Medical School, confirmed his intention to administer an oral drug mixture to volunteers, aiming to gather "evidence for age restoration in humans." This trial, if successful, would mark a pivotal development in the race to harness epigenetic reprogramming, a technology rooted in the two-decade-old discovery of genes that can revert adult cells into embryonic-like stem cells. The age-reversal effect is believed to stem from a resetting of molecular controls on DNA, known as epigenetic marks, which govern cellular metabolism and identity. While one of Sinclair’s companies, Life Biosciences, recently gained approval for an initial human trial using powerful reprogramming genes, that effort is limited to gene therapy for the eyes, targeting conditions like glaucoma. Sinclair’s new plan, however, is far bolder: a whole-body reprogramming drug administered orally. This chemical reprogramming method uses drug compounds to mimic the effects of embryonic genes, offering the significant advantage of traveling through the bloodstream to reach most, if not all, cells in the body, potentially promoting systemic rejuvenation. Despite the exciting prospects, some experts express caution. Sergiy Velychko, founder of Soxogen, a reprogramming company, noted that the chemical process, particularly in lab settings, often requires extremely high concentrations and isn't always effective. Sinclair has kept the exact composition of his drug candidate, code-named SL-100, highly confidential. However, he has previously published studies on "epigenetic age-reversal cocktails" that combined powerful chemicals with known supplements and commercially available medicines. James Clement, head of Betterhumans, confirmed he is running clinical trials of an oral reprogramming cocktail for Sinclair's XPrize team, leveraging existing drugs for easier human testing. Sinclair’s team is a late entrant to the XPrize Healthspan Competition, launched in 2023 and bankrolled by Saudi Arabia’s Hevolution Foundation, a major promoter of longevity research. Jamie Justice, executive director for the contest, mentioned the intense difficulty of selecting a single winner from 65 teams exploring diverse interventions, from health foods to digital trackers. All teams, including Sinclair's, are mandated to commence wider human trials this year. The broader field of reprogramming research is also accelerating, with startups like NewLimit, founded by crypto billionaire Brian Armstrong, recently raising $435 million to advance "age reprogramming" for organ-specific diseases. Sinclair remains convinced that whole-body rejuvenation is achievable, viewing chemical reprogramming as the most practical strategy for widespread application compared to gene therapy. His lab is actively searching for such compounds and is now employing AI to enhance the oral agents under testing. While earlier research involved a "six-factor cocktail" that included ingredients like forskolin and the antidepressant tranylcypromine, Sinclair asserts significant advancements. He emphasizes that extensive, unpublished animal studies have been conducted to ensure both safety and efficacy before any data is publicly released, underscoring a commitment to rigorous scientific validation.